US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo Q1 2024 Interim Report

    Starting 2024 with a positive EBITDAQ1 2024 highlights›     Total net revenues of SEK 139.3 m (158.8)›     EBITDA of SEK 15.9 m (-41.1) ›     Net earnings of SEK -8.9 m (-63.9)›     US Commercial segment net revenues of SEK 129.3 m (140.3), in local currency USD 12.4 m (13.5)›     Cash flow from operating activities of SEK -18.9 m (-61.6), cash and invested funds of SEK 198.0 m (278.9)›     Earnings per share before and after dilution amounted to SEK -0.26 (-1.86)›     MODIA® and Vorvida® were reimbursed within the US Veterans Affairs Federal Supply Schedule as of January 1,

    Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids

    · The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US · The study demonstrated no statistically significant difference between treatment arms in any pre-specified endpoint · Both treatment arms had unexpectedly high rates of treatment response, with no adverse events associated with the use of MODIA  · A post hoc analysis found that patients completing all 24 modules of MODIA had a significantly higher treatment response than those who did not complete the entire program · Orexo will continue to commercialize MODIA as a mobile

    Orexo publishes the Annual and Sustainability Report for 2022

    Uppsala, Sweden - March 28, 2023 – Orexo’s Annual and Sustainability Report for 2022 has been published and can be downloaded at, www.orexo.com, where it is also available in Swedish in accordance with the European Single Electronic Format (ESEF). A PDF version of the report is attached to this press release.   Nikolaj Sørensen, President and CEO: “By finalizing the development of OX124, and launching MODIA®, we have improved Orexo’s offering for opioid dependent patients. Our strengthened position means that we are ready to benefit from the deregulation for physicians to treat

    Orexo Q2 2021 Interim Report

    "First commercial DTx contract signed with a large healthcare provider"Summary · Total net revenues of SEK 142.8 m (179.1) · Net earnings of SEK -73.7 m (-32.5) · EBITDA of SEK -41.1 m (-9.0) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 126.0 m (172.5), in local currency USD 15.0 m (17.8), EBIT of SEK 61.6 m (88.8) · Cash flow from operating activities of SEK -20.9 m (-7.2), cash balance of SEK 679.7 m (677.2) · Two patents for ZUBSOLV®, with protection until 2032, were issued by the US Patent and Trademark Office · First patient enrolled in pivotal study

    Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

    · The digital therapeutic can be a valuable addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD) · The study is designed to enroll an estimated 400 participants at 35 sites across the US · Orexo brings deep category expertise to the research effort, having served the US OUD market extensively over the last eight years Uppsala, Sweden – July 1, 2021 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the enrollment of the first participant in the pivotal study of digital therapeutic modia™, in combination

    Orexo publishes Annual Report for 2020

    Uppsala, Sweden - March 23, 2021 – Orexo’s Annual Report for the 2020 fiscal year has been published. The Annual Report can be downloaded on the company’s website, www.orexo.com (investors/reports, presentations and audiocasts), and a PDF is also attached to this press release. “Despite a challenging year with Covid-19 we took several important steps in our ambition to diversify the business. The product portfolio was expanded with world-leading digital therapies and our flagship pharma project, OX124, progressed according to plan. With a strong financial position and continued robust

    Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

    · The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high with an increase of 21 percent[1] · The medication-assisted treatment (MAT) of opioid use disorder (OUD) requires a combination of drug and therapy treatment, where access and quality of counselling and psychosocial support are one of the main barriers to successful treatment · modia™ can help those with OUD by providing access to an evidence-based digital therapy rooted in cognitive behavioral techniques Uppsala, Sweden – February 10,

    Orexo Interim Report Q3 2020

    The new future starts to take shapeQ3 2020 highlights · Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstral® EU and US · Net earnings of SEK -84.9 m (111.7), net earnings of SEK -22.4 m excluding DTx launch. Net earnings also impacted by a material one-time tax adjustment of SEK -43.5 m. · EBITDA of SEK -12.2 m (114.1), EBITDA of SEK 50.3 m excluding DTx launch · US Pharma segment (ZUBSOLV® US) net revenues of SEK 143.8 m (182.7), EBIT of SEK 72.4 m (90.9)  · DTx segment EBIT of SEK -62.5 m (-), including US launch of the scientifically proven digital

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media